FutureChem Co.Ltd

FutureChem Co., Ltd. researches, develops, produces, and sells chemicals, pharmaceuticals, and medical devices in South Korea and internationally. Its radioactive pharmaceuticals include [18F]FDG for general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for lung cancer diagnosis. Its pipeline includes [18F]FC303, [177Lu]FC705, and 225Ac for prostate cancer; F-FMT for brain tumor diagnosis; FC-505 for arteriosclerosis and myocardial infarction; FC-211 for Alzheimer's disease; FC-2 for hypoxia; FC-3 for solid cancer; FC801 for bladder cancer; and FC901 for pulmonary fibrosis. The company also provides automatic synthesis equipment such as sCUBE-RXN, sCUBE-P&F, and sCUBE-M, along with molecular imaging device airway sleeves and disposable cartridges, and engages in medical device wholesale and healthcare businesses. Founded in 1999, it is headquartered in Seoul, South Korea.